BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 16487438)

  • 1. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial.
    Eustatia-Rutten CF; Corssmit EP; Pereira AM; Frölich M; Bax JJ; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):284-91. PubMed ID: 16487438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose tolerance and lipid profile in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomised controlled trial.
    Heemstra KA; Smit JW; Eustatia-Rutten CF; Heijboer AC; Frölich M; Romijn JA; Corssmit EP
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):737-44. PubMed ID: 17121524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study.
    Smit JW; Eustatia-Rutten CF; Corssmit EP; Pereira AM; Frölich M; Bleeker GB; Holman ER; van der Wall EE; Romijn JA; Bax JJ
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6041-7. PubMed ID: 16131580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
    Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
    Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Well-being, health-related quality of life and cardiovascular disease risk profile in women with subclinical thyroid disease - a community-based study.
    Bell RJ; Rivera-Woll L; Davison SL; Topliss DJ; Donath S; Davis SR
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):548-56. PubMed ID: 17371474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of procollagen III peptide as a marker of tissue hyperthyroidism in long-term treated women with TSH suppressive doses of thyroxine.
    Zulewski H; Siggelkow H; Walden C; Becker W; Hüfner M
    Exp Clin Endocrinol Diabetes; 1999; 107(3):190-4. PubMed ID: 10376444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy.
    Taillard V; Sardinoux M; Oudot C; Fesler P; Rugale C; Raingeard I; Renard E; Ribstein J; du Cailar G
    Clin Endocrinol (Oxf); 2011 Nov; 75(5):709-14. PubMed ID: 21645022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
    Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
    Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid function, cardiovascular events, and mortality in diabetic hemodialysis patients.
    Drechsler C; Schneider A; Gutjahr-Lengsfeld L; Kroiss M; Carrero JJ; Krane V; Allolio B; Wanner C; Fassnacht M
    Am J Kidney Dis; 2014 Jun; 63(6):988-96. PubMed ID: 24315768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hypothalamic-pituitary-thyroid axis in subjects with subclinical thyroid diseases: the impact of the negative feedback mechanism.
    Falaschi P; Martocchia A; Proietti A; D'Urso R; Gargano S; Culasso F; Rocco A
    Neuro Endocrinol Lett; 2004 Aug; 25(4):292-6. PubMed ID: 15361820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of chronic subclinical hyperthyroidism from levothyroxine on cardiac morphology and function].
    Biondi B; Fazio S; Palmieri EA; Tremalaterra R; Angellotti G; Bonè F; Riccio G; Cittadini A; Lombardi G; Saccà L
    Cardiologia; 1999 May; 44(5):443-9. PubMed ID: 10389349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive functions and mood during chronic thyrotropin-suppressive therapy with L-thyroxine in patients with differentiated thyroid carcinoma.
    Jaracz J; Kucharska A; Rajewska-Rager A; Lacka K
    J Endocrinol Invest; 2012 Sep; 35(8):760-5. PubMed ID: 21986400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autonomic nervous system function in chronic exogenous subclinical thyrotoxicosis and the effect of restoring euthyroidism.
    Eustatia-Rutten CF; Corssmit EP; Heemstra KA; Smit JW; Schoemaker RC; Romijn JA; Burggraaf J
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2835-41. PubMed ID: 18397977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment with L-thyroxine for differentiated thyroid carcinoma].
    Łacka K
    Wiad Lek; 2001; 54 Suppl 1():368-72. PubMed ID: 12182051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
    Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
    Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The T index in the elderly with altered values of free thyroxine and/or thyrotropin. A new thyroid diagnostic-therapeutic index].
    Tellini U; Olivieri D; Pellizzari L
    Minerva Med; 2000; 91(11-12):275-82. PubMed ID: 11253708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer.
    Montesano T; Durante C; Attard M; Crocetti U; Meringolo D; Bruno R; Tumino S; Rubello D; Al-Nahhas A; Colandrea M; Maranghi M; Travascio L; Ronga G; Torlontano M
    Biomed Pharmacother; 2007 Sep; 61(8):468-71. PubMed ID: 17553654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.